Related references
Note: Only part of the references are listed.The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
J. A. Ledermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling
Yue Zhang et al.
NATURE CELL BIOLOGY (2011)
Ubiquitin Ligase RNF146 Regulates Tankyrase and Axin to Promote Wnt Signaling
Marinella G. Callow et al.
PLOS ONE (2011)
Ex vivo supplementation with nicotinic acid enhances cellular poly(ADP-ribosyl)ation and improves cell viability in human peripheral blood mononuclear cells
Kathrin Weidele et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
R. A. Daniel et al.
BRITISH JOURNAL OF CANCER (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Toward a unified nomenclature for mammalian ADP-ribosyltransferases
Michael O. Hottiger et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
Mark Watson et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A. Huang et al.
NATURE (2009)
Nampt: linking NAD biology, metabolism and cancer
Antje Garten et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2009)
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Christopher J. Lord et al.
DNA REPAIR (2008)
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner et al.
EMBO JOURNAL (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Minimizing the risk of reporting false positives in large-scale RNAi screens
Christophe J. Echeverri et al.
NATURE METHODS (2006)
Analysis of cell-based RNAi screens
Michael Boutros et al.
GENOME BIOLOGY (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Share Paper
